Current Edition

bio

Bluebird Bio has ‘doubts’ about continuing to do business through 2022, announces CFO resignation

With two of its prized gene therapies on clinical hold and another, Zynteglo, pulled from the market in Europe seven months ago after it was …

Continue Reading →
activation

Treos Bio Announces Activation of U.S. Clinical Trial Site for Phase 1 Study of PolyPEPI™ Precision Cancer Vaccine for Patients with Metastatic Colorectal Cancer

Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion diagnostics, today said it had successfully activated its clinical trial …

Continue Reading →